At the 2026 NCCN Annual Meeting, CURE sat down with Dr. Thomas Flaig to discuss the rapidly evolving landscape of bladder ...
A new study suggests that a urine-based biomarker test shows promise in forecasting bladder cancer treatment response, which ...
A drug that helps the immune system find cancer cells also helps patients avoid having their bladders surgically removed ...
ANKTIVA approved for patients with certain indications of non-muscle invasive bladder cancer and non-small cell lung cancer -- Commercial availability achieved within two months of announcing MENA ...
A drug that helps the immune system find cancer cells also helps patients avoid having their bladders surgically removed (cystectomy), a new study ...
A drug that helps the immune system find cancer cells also helps patients avoid having their bladders surgically removed (cystectomy), a new study shows.
At the 2026 NCCN Annual Meeting, Dr. Charles Peyton spoke with CURE about how a growing number of treatment options is ...
Explore surgical options for metastatic bladder cancer, including radical cystectomy and metastasectomy. Learn how surgery ...
ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that ANKTIVA® (nogapendekin alfa ...
Pfizer (NYSE:PFE) received U.S. FDA Priority Review for a supplemental Biologics License Application covering PADCEV plus ...
Merck MRK announced that the FDA has accepted the two supplemental biologics license applications (sBLAs) seeking approval for both intravenous (“IV”) and subcutaneous (under the skin or SC) ...
Qlucore, listed on Nasdaq First North, is launching a new Qlucore Insights test (Research Use Only) specifically developed for bladder cancer samples. The software-based test delivers multiple ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results